{
    "id": 25272,
    "fullName": "ERBB4 G1109C",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB4 G1109C lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). G1109C confers a gain of function to the Erbb4 protein as demonstrated by increased phosphorylation of Erbb4 compared to wild-type and the ability to transform cells (PMID: 27207775).",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2066,
        "geneSymbol": "ERBB4",
        "terms": [
            "ERBB4",
            "ALS19",
            "HER4",
            "p180erbB4"
        ]
    },
    "variant": "G1109C",
    "createDate": "08/22/2016",
    "updateDate": "03/13/2017",
    "referenceTranscriptCoordinates": {
        "id": 148177,
        "transcript": "NM_005235",
        "gDna": "chr2:g.211387009C>A",
        "cDna": "c.3325G>T",
        "protein": "p.G1109C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Tarceva (erlotinib) in culture (PMID: 27207775).",
            "molecularProfile": {
                "id": 26082,
                "profileName": "ERBB4 G1109C"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7888,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) treatment induced apoptosis in head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775).",
            "molecularProfile": {
                "id": 26082,
                "profileName": "ERBB4 G1109C"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7886,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Erbitux (cetuximab) in culture (PMID: 27207775).",
            "molecularProfile": {
                "id": 26082,
                "profileName": "ERBB4 G1109C"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26082,
            "profileName": "ERBB4 G1109C",
            "profileTreatmentApproaches": [
                {
                    "id": 16765,
                    "name": "Lapatinib",
                    "profileName": "ERBB4 G1109C"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 148177,
            "transcript": "NM_005235",
            "gDna": "chr2:g.211387009C>A",
            "cDna": "c.3325G>T",
            "protein": "p.G1109C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}